{"url":"https://whatshealthyandwhy.com/senolytics/clearing-zombie-cells","path":"/senolytics/clearing-zombie-cells","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/senolytics/clearing-zombie-cells.json","markdown":"https://whatshealthyandwhy.com/senolytics/clearing-zombie-cells.md"},"topic":{"slug":"senolytics","name":"Senolytics","url":"https://whatshealthyandwhy.com/senolytics"},"slug":"clearing-zombie-cells","order":1,"title":"Clearing Zombie Cells","question":"Do senolytic supplements slow aging in people?","answer":"Senolytics may clear aged cells and improve physical function in people, but proof so far is from mice and two tiny uncontrolled human studies.","description":"How senolytic compounds selectively eliminate senescent cells to slow aging, reduce inflammation, and extend healthspan","confidence":2,"confidenceNote":"Strong mouse data (lifespan up 36% with D+Q); human evidence is two open-label studies with no control group (14 and 9 patients).","evidenceSummary":{"rctCount":0,"observationalCount":2,"metaAnalysisCount":0,"totalParticipants":"23","replicated":false,"newestStudyYear":2020},"category":{"categoryTitle":"Your Body","categorySlug":"your-body","subcategoryName":"Body Systems","subcategorySlug":"systems","url":"https://whatshealthyandwhy.com/explore/your-body/systems"},"actions":["Exercise regularly; resistance training in particular reduces senescence markers in skeletal muscle.","Eat strawberries and other fruit that contain fisetin; its anti-senescence effects are so far shown in mice and cells, not people [3].","Ask a doctor before trying any senolytic supplement; studied regimens are short intermittent pulses of 2–3 days, since daily dosing adds side effects."],"cautions":["Dasatinib is a prescription cancer drug with known side effects and is not available for general purchase.","People taking anticoagulants or immunosuppressants, or having cancer treatment, should consult a physician before any senolytic.","Long-term safety in healthy people is limited, and large placebo-controlled trials with hard outcomes such as disease or death are still lacking."],"simpleText":"As cells age, some stop dividing but refuse to die — they accumulate in tissues, continuously leaking inflammatory proteins that damage neighboring healthy cells. These senescent cells, sometimes called \"zombie cells,\" build up throughout the body over decades and contribute to arthritis, heart disease, metabolic dysfunction, frailty, and cognitive decline. Senolytics are compounds that selectively clear these damaged cells while leaving healthy tissue intact. In animal studies, even brief periodic treatment with senolytics has improved physical function, reduced disease burden, and extended lifespan by meaningful margins [1][2]. The first human clinical trials have now confirmed that senescent cell burden can be reduced in people, with improvements in physical function observed [4][5]. The field is young but the foundational science is unusually rigorous.","mediumText":"What Senescent Cells Are and Why They Matter\n\nCellular senescence is a normal biological state in which a damaged or stressed cell permanently stops dividing. This is actually a protective mechanism — a cell that has accumulated DNA damage should not replicate, because replication could produce cancerous offspring. In younger people, the immune system efficiently clears these stalled cells. The problem develops gradually: with age, clearance slows while accumulation accelerates, and senescent cells begin piling up in fat tissue, joints, arteries, the brain, lungs, liver, and kidneys.\n\nWhat makes senescent cells destructive is not their presence alone but what they secrete. These cells produce a persistent stream of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, or SASP. SASP signals promote inflammation in surrounding tissue, degrade the extracellular matrix, push neighboring cells into senescence (a \"bystander effect\"), and interfere with tissue repair. Even a relatively small number of senescent cells — studies have shown as few as transplanted cells representing 1–5% of total cell population in young mice — can cause measurable physical dysfunction within a few weeks [2].\n\nKey cellular markers of senescence include elevated p16^INK4a and p21^CIP1 (cell cycle arrest proteins), positive senescence-associated beta-galactosidase (SA-β-gal) activity, and increased secretion of IL-6, IL-8, MMP-3, and PAI-1. These have become the standard readouts in both animal studies and early human trials.\n\nThe Senolytic Approach\n\nSenolytics work by exploiting a vulnerability in senescent cells. Despite having stopped dividing, senescent cells are not passive — they actively resist programmed cell death (apoptosis) by upregulating anti-apoptotic survival pathways, particularly BCL-2, BCL-XL, and PI3K/Akt signaling. They depend on these pathways to survive indefinitely in tissue. Senolytic drugs and compounds inhibit these pathways, tipping senescent cells into apoptosis while normal cells — which rely less heavily on these specific survival signals — are left unaffected.\n\nThis selectivity is the central claim of senolytics research, and it has held up reasonably well across many different cell types and animal models, though the degree of selectivity varies by compound and tissue.\n\nThe Most-Studied Senolytic Compounds\n\nDasatinib + Quercetin (D+Q)\nThe combination of the FDA-approved cancer drug dasatinib (100 mg) and the natural flavonoid quercetin (1,000 mg) is the most clinically studied senolytic regimen. Dasatinib kills senescent preadipocytes and certain immune cells; quercetin kills senescent endothelial and other cell types. Together, they cover a broader range of senescent cell populations than either compound alone. Both drugs inhibit the BCL-2/BCL-XL and PI3K/Akt pathways through different mechanisms, which explains the synergy. In clinical trials, the protocol has been intermittent rather than daily — typically 3 consecutive days per cycle, repeated monthly or every few months. Dasatinib is a prescription drug with known side effects and is not available for general purchase; quercetin is widely available as a supplement.\n\nFisetin\nFisetin, a flavonol found in strawberries and other fruits, showed the strongest senolytic activity of ten tested flavonoids in a 2018 Mayo Clinic screen [3]. It reduces senescent cell markers across fat, liver, lung, and brain tissue in aged mice, and extended lifespan meaningfully when given late in life — starting at roughly the equivalent of age 75 in humans. Fisetin is often taken in intermittent \"pulse\" protocols (500–1,000 mg over 2–3 consecutive days, monthly) to mimic the hit-and-run dosing strategy that worked in rodent studies. Bioavailability from standard powder supplements is poor; liposomal or hydrogel formulations improve absorption substantially.\n\nNavitoclax (ABT-263)\nNavitoclax is a potent BCL-2/BCL-XL inhibitor developed as a cancer drug. It is one of the most powerful senolytics identified, but causes thrombocytopenia (platelet reduction) because platelets also rely on BCL-XL for survival. It is not used outside clinical research settings but is an important tool for understanding senolytic mechanisms.\n\nQuercetin alone\nAt higher doses (500–1,000 mg), quercetin has measurable senolytic activity in preclinical models even without dasatinib, particularly in vascular endothelial cells. It's widely available, has a strong general safety profile, and has well-established anti-inflammatory effects through other mechanisms. Many people use it in the context of senolytics given its accessibility, though its senolytic potency alone is lower than the D+Q combination.\n\nNatural Lifestyle Senolytics\n\nSeveral common interventions may support senescent cell clearance through complementary mechanisms:\n\n- Exercise — Acute and chronic exercise reduces markers of senescence in muscle, fat, and liver tissue. Resistance training in particular reduces p16+ cell burden in skeletal muscle. This is thought to work partly through improved immune clearance and partly through direct anti-apoptotic pathway modulation.\n- Caloric restriction and fasting — Extended fasting enhances autophagy and immune surveillance, both of which help clear senescent cells. Time-restricted eating and periodic longer fasts (36–72 hours) are the most studied protocols in this context.\n- Rapamycin — The mTOR inhibitor rapamycin reduces SASP in senescent cells and has extended lifespan in every mammalian species tested, though it is immunosuppressive and used only under medical supervision.\n\nSafety Considerations\n\nThe intermittent \"pulse\" dosing strategy (a few days per cycle) was deliberately designed to limit side effects. Continuous daily senolytic dosing causes more side effects and may not be more effective — the goal is to trigger senescent cell apoptosis and then allow time for tissue recovery. Most reported adverse effects in clinical trials have been mild and transient, including GI symptoms, fatigue, and superficial edema.\n\nBecause many senolytics affect BCL-2 family proteins, people taking anticoagulants, immunosuppressants, or undergoing cancer treatment should consult a physician before using these compounds. Quercetin and fisetin have generally clean safety profiles at the doses used, but the field is early and long-term safety data in healthy humans are limited.\n\nFor related topics, see our fisetin page, quercetin page, autophagy page, and telomeres page.","deepText":"Evidence Review\n\nFoundational Animal Study: Baker et al. 2011\n\nThe study that launched the modern senolytic field appeared in Nature in 2011 (PMID 22048312). Baker and colleagues at the Mayo Clinic used a transgenic mouse model (INK-ATTAC) that allowed them to selectively kill p16^INK4a-expressing senescent cells by administering a drug (AP20187). Working in BubR1 progeroid mice — which age rapidly and accumulate senescent cells early — they showed that lifelong clearance of p16+ cells significantly delayed the onset of age-related pathologies in three tissues: adipose tissue (fat loss and dysfunction), skeletal muscle (weakness, reduced fiber cross-section), and eye (cataracts). Animals with cleared senescent cells maintained better tissue architecture throughout life and showed delayed development of all three phenotypes compared to untreated controls.\n\nThis was the first direct demonstration that cellular senescence is causally involved in generating age-related tissue dysfunction, not merely a correlate of aging. The study established that the accumulation of senescent cells is reversible and that its reversal has measurable biological consequences. It generated enormous interest in pharmacological strategies to achieve senescent cell clearance without genetic engineering.\n\nSenolytic Compounds Extend Lifespan: Xu et al. 2018\n\nXu et al. published in Nature Medicine (PMID 29988130) the key translational step: demonstrating that pharmacological senolytic treatment in wild-type aged mice produces the same benefits seen in the Baker transgenic model. The study used dasatinib plus quercetin (D+Q) as the senolytic intervention.\n\nIn one set of experiments, young mice (4–5 months) received transplants of a small number of senescent cells (representing ~1–3% of total cell count) from tissue culture. Within 14 days, transplanted mice showed significantly worse performance on physical function tests — grip strength, treadmill endurance, gait speed — compared to mice that received non-senescent cells. This result was striking because it showed that a numerically small senescent cell burden, if chronically present, is sufficient to impair physical function in an otherwise healthy young animal.\n\nCritically, when these senescent-cell-transplanted young mice were then treated with D+Q, physical function was restored. In naturally aged mice (20–22 months, roughly equivalent to 70+ years in humans), intermittent D+Q treatment (3 days on, 2 weeks off) improved treadmill walking speed, grip strength, and daily physical activity. Post-treatment median survival in aged mice increased by 36%, and mortality hazard was reduced to 65% of control values. The intervention began late in life (equivalent to advanced age in humans), making these results particularly relevant for clinical translation.\n\nFirst-in-Human Senolytic Trial: Justice et al. 2019\n\nJustice et al. published in EBioMedicine (PMID 30616998) the first clinical use of senolytics in humans. Fourteen patients with idiopathic pulmonary fibrosis (IPF) — a fatal, progressive lung disease strongly associated with cellular senescence — received intermittent D+Q (dasatinib 100 mg/day plus quercetin 1,250 mg/day, 3 days/week for 3 weeks). The primary outcome was feasibility and tolerability; secondary outcomes included physical function.\n\nAll 14 patients completed the protocol with no serious adverse events attributed to the drugs. Physical function improved significantly: 6-minute walk distance increased by a mean of ~21 meters, and physical performance (chair-stand time, 4-meter gait speed) also improved. While the trial was open-label, non-randomized, and had no control group — substantial limitations — the magnitude of functional improvement in a disease that is relentlessly progressive was notable. IPF patients characteristically decline continuously; any measurable improvement in physical function over a 3-week senolytic course was considered a meaningful signal warranting further investigation.\n\nHuman Tissue Senescent Cell Reduction: Hickson et al. 2019\n\nHickson et al. (PMID 31542391) provided the first direct evidence that D+Q reduces senescent cell burden in human tissue. Nine patients with diabetic kidney disease (mean age 68.7 years) received a single 3-day course of oral D+Q (dasatinib 100 mg/day, quercetin 1,000 mg/day). Adipose tissue biopsies were taken before treatment and 11 days after the last dose.\n\nPost-treatment biopsies showed significant reductions in multiple independent senescence markers: p16^INK4a-expressing cells declined by approximately 30–70% depending on the marker, p21^CIP1-expressing cells declined similarly, SA-β-galactosidase-positive cells fell, and adipocyte progenitors with limited replicative potential decreased. Plasma levels of SASP-associated factors (MMP-2, MMP-9, IL-1α, IL-6) also fell modestly. This study established that the senolytic approach translates to human tissue — that D+Q genuinely reduces senescent cell markers in vivo, not just in cell culture or animal models. Sample size was very small (n=9), and there was no control group, but the directional consistency across multiple independent senescence markers strengthens confidence in the finding.\n\nFisetin as a Natural Senolytic: Yousefzadeh et al. 2018\n\nThis Mayo Clinic study (PMID 30279143) systematically screened ten flavonoids for senolytic activity in senescent human and murine cells in vitro, then tested the most promising compound in multiple mouse models. Fisetin emerged as the most potent flavonoid tested, outperforming quercetin, luteolin, kaempferol, apigenin, and others across several senescence endpoints. …","deepTruncated":true,"references":[{"id":"1","title":"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders","authors":"Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM","year":2011,"journal":"Nature","pmid":"22048312","url":"https://pubmed.ncbi.nlm.nih.gov/22048312/"},{"id":"2","title":"Senolytics improve physical function and increase lifespan in old age","authors":"Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, et al.","year":2018,"journal":"Nature Medicine","pmid":"29988130","url":"https://pubmed.ncbi.nlm.nih.gov/29988130/"},{"id":"3","title":"Fisetin is a senotherapeutic that extends health and lifespan","authors":"Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Kirkland JL","year":2018,"journal":"EBioMedicine","pmid":"30279143","url":"https://pubmed.ncbi.nlm.nih.gov/30279143/"},{"id":"4","title":"Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study","authors":"Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Kirkland JL","year":2019,"journal":"EBioMedicine","pmid":"30616998","url":"https://pubmed.ncbi.nlm.nih.gov/30616998/"},{"id":"5","title":"Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","authors":"Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Tchkonia T","year":2019,"journal":"EBioMedicine","pmid":"31542391","url":"https://pubmed.ncbi.nlm.nih.gov/31542391/"},{"id":"6","title":"Senolytic drugs: from discovery to translation","authors":"Kirkland JL, Tchkonia T","year":2020,"journal":"Journal of Internal Medicine","pmid":"32686219","url":"https://pubmed.ncbi.nlm.nih.gov/32686219/"}],"wordCount":2220,"source":{"path":"src/content/topics/senolytics/clearing-zombie-cells.md"},"citeAs":"“Do senolytic supplements slow aging in people?.” What's Healthy and Why. https://whatshealthyandwhy.com/senolytics/clearing-zombie-cells","notice":"General information backed by peer-reviewed research, not medical advice."}